Literature DB >> 11124641

Treatment of cystic fibrosis in the adult.

M E Hodson1.   

Abstract

There has been a dramatic increase in the life expectancy of patients with cystic fibrosis (CF) over the last 20 years. CF used to be fatal in childhood but now, over a third of the patients are adults. The reasons for improved survival are multi-factorial. The disease affects most systems of the body although the majority of morbidity and mortality is due to lung disease. As in any life-threatening disease, in addition to medical issues, there are many psychosocial and spiritual issues, which need attention. Transition from paediatric to adult care needs to be handled very sensitively. Arranging a balanced and reliable system of care - out-patient, in-patient and home care - is essential to ensure the patient's survival and quality of life is as good as possible. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 11124641     DOI: 10.1159/000056287

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis.

Authors:  A E Holland; L Denehy; G Ntoumenopoulos; M T Naughton; J W Wilson
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 2.  Posture and cystic fibrosis.

Authors:  R Tattersall; M J Walshaw
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 3.  Structure and function of the mucus clearance system of the lung.

Authors:  Brenda M Button; Brian Button
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

Review 4.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

5.  The impact of single gene and chromosomal disorders on hospital admissions in an adult population.

Authors:  Danielle E Dye; Kate J Brameld; Susannah Maxwell; Jack Goldblatt; Peter O'Leary
Journal:  J Community Genet       Date:  2011-03-02

6.  A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Authors:  Alexander Chuchalin; Eszter Csiszér; Kàlmàn Gyurkovics; Maria Trawińska Bartnicka; Dorota Sands; Nikolai Kapranov; Guido Varoli; Pier Alessandro Monici Preti; Henryk Mazurek
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

7.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Linsey Abbott; Amanda Plummer; Zhe Hui Hoo; Martin Wildman
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.